Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Ending the COVID-19 Pandemic Hinges on Trust: Science alone won’t pull us out of the pandemic.

1 Dec, 2021 | 09:47h | UTC

Ending the COVID-19 Pandemic Hinges on Trust – Think Global Health

 

Commentary on Twitter

 

Using wearable data, a real-time alerting system can be used for the early detection of Covid-19 and other stress events.

1 Dec, 2021 | 09:59h | UTC

Real-time alerting system for COVID-19 and other stress events using wearable data – Nature Medicine

Commentary: Scientists develop a smartwatch-based device for early detection of COVID-19 – News Medical

 

Commentary on Twitter

 

Another randomized trial showed convalescent plasma does not benefit patients hospitalized with Covid-19.

1 Dec, 2021 | 09:49h | UTC

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Related:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Commentary on Twitter

 

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions.

1 Dec, 2021 | 08:54h | UTC

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions – Journal of Clinical Epidemiology

 

Cohort study: Allergic conditions linked to lower COVID-19 infection risk.

1 Dec, 2021 | 08:52h | UTC

News Release: Allergic conditions linked to lower COVID-19 infection risk – BMJ

Original Study: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax

 

Global estimates of viral suppression in 31 countries shows too many people with HIV fail to achieve durable viral suppression.

1 Dec, 2021 | 08:41h | UTC

News Release: Too many people with HIV fail to achieve durable viral suppression – NIH News Releases

Original Study: Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries – The Lancet HIV (link to abstract – $ for full-text)

 

WHO Technical Brief and Priority Actions: Enhancing Readiness for Omicron.

30 Nov, 2021 | 08:46h | UTC

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States – World Health Organization

Commentaries:

The World Health Organization warns of very high risk posed by the omicron variant – NPR

Omicron Covid variant poses very high global risk, says WHO – The Guardian

See also the latest articles on the subject:

Statement On Omicron Variant – Infectious Diseases Society of America

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear – The BMJ

Helen Salisbury: Omicron—panic mongering or appropriate caution? – The BMJ

The Omicron variant underscores the global stakes of Covid-19 vaccine inequity – STAT

EXPLAINER: What we know and don’t know about omicron variant – Associated Press

Omicron: How do you detect it? – BBC

Are new COVID variants like Omicron linked to low vaccine coverage? Here’s what the science says – The Conversation

Omicron: why the WHO designated it a variant of concern – The Conversation

It looks like Omicron causes milder illness – is this how COVID becomes endemic? – The Conversation

As Omicron spreads, studies suggest that travel bans alone don’t do much good – NPR

 

RCT: SARS-CoV-2 transmission was largely prevented through a comprehensive preventive intervention in a large, live, indoor gathering event.

30 Nov, 2021 | 08:43h | UTC

Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial – The Lancet Infectious Diseases

Invited Commentary: Concerts and COVID: can the beat go on? – The Lancet Infectious Diseases

Related: No COVID-19 cases found after a well-controlled indoor concert.

 

Commentary on Twitter

 

Preliminary RCT found prostacyclin may improve outcomes in mechanically ventilated patients with COVID-19 and severe endotheliopathy.

30 Nov, 2021 | 08:42h | UTC

Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial – American Journal of Respiratory and Critical Care Medicine

News release: Well-known drug could help the most severely affected COVID-19 patients in intensive-care departments – by University of Copenhagen

 

Commentary from the author on Twitter (thread – click for more)

 

Electrocardiogram monitoring in the prone position in Covid-19 acute respiratory distress syndrome.

30 Nov, 2021 | 08:38h | UTC

Electrocardiogram monitoring in the prone position in coronavirus disease 2019 acute respiratory distress syndrome – European Journal of Cardiovascular Nursing

 

Commentary on Twitter

 

ESCMID COVID-19 Living guidelines: drug treatment and clinical management.

30 Nov, 2021 | 08:40h | UTC

ESCMID COVID-19 Living guidelines: drug treatment and clinical management – Clinical Microbiology and Infection

 

WHO Update on Omicron + Several Articles on the Subject.

28 Nov, 2021 | 21:38h | UTC

Update on Omicron – World Health Organization

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern – World Health Organization

See also:

Omicron COVID-19 variant: Africa CDC statement

Expert reaction to B.1.1.529 variant situation in South Africa; and UK travel restrictions in response – Science Media Centre

Threat Assessment Brief: Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern (Omicron) for the EU/EEA – European Centre for Disease Prevention and Control

‘Patience is crucial’: Why we won’t know for weeks how dangerous Omicron is – Science

Scientists rapidly identified the Omicron variant. But firm answers about its impact could take weeks – STAT

New Covid variant: Will new measures against Omicron work? – BBC

Vaccine inequity and hesitancy made the Omicron variant more likely, scientists say – CNN

Travel bans aren’t the answer to stopping new COVID variant Omicron – The Conversation

Scientists sharing Omicron data were heroic. Let’s ensure they don’t regret it – The Guardian

The Omicron variant reveals the true global danger of ‘vaccine apartheid’ – The Guardian

We Know Almost Nothing About the Omicron Variant – The Atlantic

Covid: New Omicron variant not a disaster, says Sage scientist – BBC

New Covid variant: Will new measures against Omicron work? – BBC

World is put on high alert over the Omicron coronavirus variant – CNN

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant – Moderna

Omicron is the new COVID kid on the block: five steps to avoid, ten to take immediately – The Conversation

What’s known and unknown about Omicron, the coronavirus variant identified in South Africa – STAT

The new variant is worrying – but it doesn’t change how we tackle Covid – The Guardian

Omicron: everything you need to know about new Covid variant – The Guardian

Omicron variant unlikely to reboot Covid in UK, expert says – The Guardian

UK detects Omicron cases, as more countries eye new COVID-19 variant – CIDRAP

New COVID variant alarms researchers, triggers travel bans – CIDRAP

The omicron variant spreads across Europe as new travel bans take effect – NPR

What to know about omicron, the new COVID variant – NPR

What we know about the Omicron variant – CNN

The new Omicron variant is a pandemic gut check – CNN

Newly discovered Covid-19 variant B.1.1.529 is ‘red flag’ but US needs to learn more, Fauci says – CNN

Omicron, a new Covid-19 variant with high number of mutations, sparks travel bans and worries scientists – CNN

What to know about the omicron variant of the coronavirus – The Washington Post

 

Commentary on Twitter (thread – click for more)

 

M-A: Observational data on the effectiveness of COVID-19 vaccines.

30 Nov, 2021 | 08:37h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 

Omicron Variant: Videos with opinions on the subject.

28 Nov, 2021 | 21:33h | UTC

 

Milestone Moment for Pandemic Treaty in Geneva – Calls for Tough Decisions by Countries.

28 Nov, 2021 | 21:28h | UTC

Milestone Moment for Pandemic Treaty in Geneva – Calls for Tough Decisions by Countries – Health Policy Watch

See also:

Countries prepare for pandemic treaty decision – The Lancet

WHO nears consensus on future international pact to prevent pandemics – diplomats – Reuters

The WHO is seeking a new treaty on handling future pandemics. It could be a hard sell – NPR

 

Commentary on Twitter

 

Too early to tell, but preliminary information from doctors in South Africa suggests the new Covid variant Omicron may be associated with less severe disease.

28 Nov, 2021 | 21:35h | UTC

 

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

28 Nov, 2021 | 21:30h | UTC

News Release: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Commentary: New data, analyses take some of the shine off Merck’s Covid pill – STAT

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Commentaries on Twitter

 

European countries mandate medical-grade masks over homemade cloth face coverings.

28 Nov, 2021 | 21:26h | UTC

European countries mandate medical-grade masks over homemade cloth face coverings – CNN

 

Editorial: Vax the world.

26 Nov, 2021 | 08:40h | UTC

Vax the world – Science

 

Commentary from the author on Twitter

 

EMA recommends approval of Pfizer-BioNTech vaccine for children aged 5 to 11.

26 Nov, 2021 | 08:47h | UTC

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

Related:

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

 

Commentary on Twitter

 

Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

See also:

Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC

WHO calls special meeting to discuss new Covid variant found in South Africa with ‘a large number of mutations’ – CNBC

New COVID-19 Variant With Multiple Concerning Mutations Identified in Southern Africa – Health Policy Watch

Scientists warn of new Covid variant with high number of mutations – The Guardian

South Africa detects new COVID variant with many mutations – MedicalXpress

 

Related commentary on Twitter (thread – click for more)

 

Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.

26 Nov, 2021 | 08:44h | UTC

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia – The Lancet Respiratory Medicine

 

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

26 Nov, 2021 | 08:35h | UTC

Persistent symptoms following SARS-CoV-2 infection among children and young people: a meta-analysis of controlled and uncontrolled studies – Journal of Infection

Related:

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

 

M-A: Comparing the clinical efficacy of COVID-19 vaccines.

26 Nov, 2021 | 08:37h | UTC

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis – Scientific Reports

 

[Preprint] Serological responses to COVID-19 booster vaccine in England.

26 Nov, 2021 | 08:34h | UTC

Serological responses to COVID-19 booster vaccine in England – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.